Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used as needed to treat migraine episodes in adults. The most common side effects include nausea, sleepiness, and ...

Ubrelvy can interact with certain medications, such as ketoconazole or phenytoin (Dilantin). Ubrelvy is not known to interact with alcohol. However, drinking alcohol during Ubrelvy treatment could ...

Ubrelvy tablets are taken as needed to treat symptoms caused by migraine episodes. You’ll take Ubrelvy when you start to have migraine symptoms. If needed, you can take another dose 2 hours later. You ...

The approval of medicines called CGRP antagonists has led to big changes in how migraine is managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...

Ubrelvy works by blocking calcitonin gene-related peptide (CGRP) receptors in your brain, which prevents CGRP from producing its effects. This helps reduce migraine symptoms. Most people experience ...

Migraine isn’t simply a “bad headache” — it’s a complex neurological disease that can affect your entire brain and body before, during, and after the painful headache attack. Since 2018, several new ...

For the roughly 40 million adults with migraine in the U.S., effective treatment is crucial; stopping an attack in its tracks can mean finishing the day instead of being stuck in bed. While triptans ...

Despite competing against several drugs that have been approved to fend off migraine headaches, AbbVie’s Ubrelvy (ubrogepant) —which is approved only to treat them—has carved out a significant niche ...

A migraine drug can help stop the devastating headaches in their tracks, allowing sufferers to go about their daily lives with little to no symptoms, a new clinical trial has found. People who took ...

AbbVie makes you the star of its new acute migraine drug ad with tennis phenom Serena Williams. Make that “U”—as in Ubrelvy. The latest TV ad in Ubrelvy’s “Anytime, Anywhere” series shows three ...

The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of ...